It has become apparent in recent years that low levels of ciculating tumor DNA can be detected in multiple myeloma (MM) patients through liquid biopsies. In this interview, Suzanne Trudel, MD, MSc, FRCPC, of the Princess Margaret Hospital, Toronto, Canada, gives an overview of how this approach may be refined in the coming years, so that it may replace the more invasive and painful bone marrow biopsy, in both clinical and research contexts.
Liquid biospy approaches for detecting MM and their optimization
